AbbVie vs Regeneron Pharmaceuticals: why the prices moved differently

• ▲

  Quarterly results beat as new drugs offset Humira's decline AbbVie's revenue rose 10.2% to $16.99 billion and adjusted earnings per share jumped 22.9% to $3.65, with Skyrizi and Rinvoq each up about 24%. Management raised full-year profit guidance, showing the company is growing again despite Humira's 35.9% sales drop. This reassures investors and supports the stock.

  The latest earnings show the core business is growing and guidance was raised, a direct positive for the stock.

• ▲

  Epcoritamab combination cuts lymphoma progression risk by 51% In a late-stage trial, AbbVie and partner Genmab's drug epcoritamab plus standard chemotherapy reduced the risk of disease worsening or death by 51% in newly diagnosed diffuse large B-cell lymphoma. This is the first such success for a bispecific antibody in frontline treatment, strengthening AbbVie's cancer pipeline and lifting hopes for a new growth driver.

  A major clinical win in a large cancer market adds a potential new revenue stream and boosts investor confidence.

• ▲

  FDA grants two breakthrough designations for Temab-A The FDA gave AbbVie's experimental antibody-drug conjugate Temab-A two Breakthrough Therapy Designations, for colorectal and non-small cell lung cancer. This speeds up development and signals the drug may offer a big advantage over existing treatments. It adds to AbbVie's growing oncology pipeline and supports long-term growth.

  Breakthrough designations can accelerate approval and highlight pipeline strength, a positive for future sales.

• ▲

  EU approves Boey, a fast-acting short-duration frown-line treatment European regulators approved Boey, the first rapid-onset, short-duration neurotoxin for frown lines, with effects starting in as little as eight hours and lasting two to three weeks. This expands AbbVie's aesthetics portfolio with a differentiated product and could capture new demand, supporting the stock.

  A new approved product in aesthetics adds revenue potential and competitive edge.

• ▲

  AbbVie selected for 340B rebate pilot, easing discount burden The Trump administration picked AbbVie as one of 10 drugmakers for a pilot that lets companies pay rebates after purchase instead of giving upfront discounts under the 340B program. This could improve cash flow and reduce compliance risk, a modest positive for the stock.

  The pilot may reduce upfront costs and regulatory friction for AbbVie.

Based on 7 stories →

• ▲

  FDA approves JUVMO for Parkinson's disease The FDA approved JUVMO (tavapadon), the first selective D1/D5 agonist for Parkinson's, with U.S. launch set for October 2026. This adds a differentiated neuroscience drug to AbbVie's portfolio, supporting future revenue growth and lifting investor confidence.

  A major new drug approval directly expands AbbVie's revenue base and pipeline strength.

• ▲

  Zumilokibart succeeds in Phase 2 atopic dermatitis trial AbbVie's zumilokibart met the main goal in a Phase 2 study for atopic dermatitis, and the mid-dose will move into final-stage testing. This strengthens the immunology pipeline and offers a potential new treatment for a common skin condition, supporting long-term growth.

  Positive mid-stage trial results advance a key pipeline candidate, signaling future revenue potential.

• ▲

  ABBV-295 shows promising weight loss and long half-life Phase 1 data for ABBV-295 showed up to 9.8% weight loss and an 11-12 day half-life, supporting less frequent dosing. This opens a new market for AbbVie in obesity care, a high-growth area, and could become a significant future sales driver.

  Early data support a potential best-in-class obesity drug, a major new growth opportunity.

• ▲

  RINVOQ shows sustained vitiligo repigmentation in Phase 3 Phase 3 data show RINVOQ produced continued skin repigmentation in vitiligo through 76 weeks with no new safety issues. This supports a potential new use for a key drug, expanding its label and adding a new revenue stream if approved.

  Late-stage data support a new indication for a major drug, enhancing its growth prospects.

Based on 9 stories →

• ▲

  Qulipta hits Phase 3 goal in menstrual migraine Qulipta met the main goal and all secondary goals in a late-stage trial for menstrual migraine, a condition with no approved treatment. If approved, it opens a new market of over nine million U.S. patients, adding a fresh sales driver and supporting the stock.

  New clinical win expands a fast-growing drug into an untapped market, a clear positive for future revenue.

• ▲

  Rinvoq wins EU approval for juvenile arthritis European regulators approved Rinvoq for polyarticular juvenile idiopathic arthritis, its 11th EU use. This widens the label of a key growth drug already on track for about $10.2 billion in 2026 sales, reinforcing confidence in AbbVie's immunology growth.

  New regulatory approval directly expands a major growth drug's market and supports the bull case.

• ▲

  AI drug-discovery deals and EPKINLY approval AbbVie signed multi-year AI collaborations with Iambic and joined the AISB Bind network to speed up drug discovery, and Health Canada approved EPKINLY for relapsed follicular lymphoma. These broaden the pipeline and add a new approved use, supporting long-term growth.

  New partnerships and a new approval show pipeline expansion and fresh revenue potential.

• ▼

  Oncology sales fall on Imbruvica and IRA pricing First-half oncology sales dropped 2.8% to $3.28 billion as Imbruvica fell 27.1% on competition and Medicare drug-price changes. Newer drugs like Venclexta and Elahere grew but did not fully offset the decline, weighing on overall growth.

  A real counterweight: a key segment is shrinking due to competition and pricing pressure.

Based on 8 stories →

• ▼

  Apogee acquisition dilutes near-term earnings AbbVie closed its $10.9 billion purchase of Apogee Therapeutics, adding an experimental immunology drug but cutting adjusted earnings by $0.14 per share in 2026 and $0.46 in 2027. Profit won't get a boost until 2032, so near-term investors see lower earnings and the stock faces pressure.

  This is the main new negative event this period and directly lowers reported earnings, a key driver of the stock price.

• ▲

  Etentamig succeeds in Phase 3 myeloma trial AbbVie's experimental blood-cancer drug etentamig met both main goals in a late-stage trial, with a 74% response rate versus 46% for standard care and a 60% lower risk of disease worsening. This strengthens the oncology pipeline and raises hopes for a new growth driver, supporting the stock.

  This is a major new clinical win that expands AbbVie's cancer franchise and improves long-term growth prospects.

• ▲

  Qulipta succeeds in menstrual migraine trial AbbVie's migraine drug Qulipta hit the main goal in a Phase 3 trial for menstrual migraine, reducing migraine days with a convenient dosing schedule. Qulipta sales already grew 31% to $350 million last quarter, so a new use could add revenue and lift the stock.

  This is a new positive trial result that could expand the label and sales of an already fast-growing drug.

• ▲

  Neuroscience outlook raised on broad growth AbbVie lifted its 2026 neuroscience revenue forecast to about $12.7 billion and total revenue to roughly $67.6 billion, after first-half neuroscience sales jumped 21.8%. Strong demand across Vraylar, Botox, Qulipta, Ubrelvy and Vyalev gives investors more confidence in future profits, pushing the stock up.

  This is a new guidance raise that directly improves revenue expectations and signals broad-based demand strength.

Based on 8 stories →

• ▲

  Citadel boosts AbbVie stake by 547% Ken Griffin's Citadel bought 2.68 million more ABBV shares, a 547% increase, at an average of $214.90. A major fund raising its bet signals confidence in AbbVie's long-term value and can draw other investors in, supporting the stock price.

  Large institutional buying is a fresh, concrete signal of confidence that can lift investor sentiment and demand for the shares.

• ▲

  New lung cancer data strengthens oncology pipeline AbbVie presented promising early data for several experimental lung cancer drugs at a major conference, with high response rates and manageable side effects. This broadens its pipeline beyond immunology and neuroscience, giving investors another potential growth engine and supporting the stock.

  Fresh clinical progress on multiple oncology programs adds a new growth pillar, which can improve the long-term earnings outlook.

• ▲

  Skyrizi submitted for easier Crohn's dosing in Europe AbbVie asked European regulators to approve Skyrizi as a subcutaneous (under-the-skin) induction treatment for Crohn's disease, based on positive trial data. If approved, it offers patients a more convenient option and extends Skyrizi's reach, supporting future sales and the stock.

  A regulatory filing that could widen a key drug's use is a concrete pipeline expansion, not just a repeat of past results.

• ▼

  J&J's oral psoriasis pill approved in China Johnson & Johnson won Chinese approval for Icotyde, a once-daily pill for plaque psoriasis, a market with over 8.4 million patients where AbbVie's Skyrizi competes. A convenient oral option could take share from injectables like Skyrizi, weighing on AbbVie's growth prospects in China.

  This is a new competitive threat in a large market that could pressure sales of a key AbbVie drug.

Based on 7 stories →

• ▼

  Trump demands drug price cuts President Trump sent letters to major drugmakers, including AbbVie, demanding U.S. prescription price cuts within 60 days. This threatens future pricing power and revenue, pushing the stock down as investors worry about lower profits.

  This is a new regulatory threat that directly pressures AbbVie's pricing and future earnings.

• ▲

  Skyrizi and Rinvoq fuel growth AbbVie's newer immunology drugs Skyrizi and Rinvoq now make up over 47% of total revenue, with combined sales expected to exceed $31 billion this year. Their rapid growth is replacing declining Humira sales and supports the stock's long-term value.

  This shows the core business is successfully transitioning beyond Humira, a key driver of future revenue.

• ▲

  Neuroscience outlook raised AbbVie raised its 2026 neuroscience revenue forecast to about $12.7 billion, driven by strong sales of Vraylar, migraine drugs Ubrelvy and Qulipta, and Botox Therapeutic. This diversification adds a growing revenue stream and boosts investor confidence.

  This is a new positive update showing another part of AbbVie's business is performing well and raising guidance.

• ▼

  Epcoritamab trial fails survival goal Genmab and AbbVie confirmed that the Phase 3 trial of epcoritamab for a type of lymphoma did not meet its main overall survival goal. This pipeline setback could delay or reduce the drug's potential, weighing on sentiment.

  This is a new negative pipeline event that could hurt future oncology revenue prospects.

Based on 9 stories →

• ▲

  Q2 beat and raised revenue guidance AbbVie beat Q2 estimates with $3.65 EPS and $16.99B revenue, and raised full-year revenue guidance by $300M on strong Skyrizi, Rinvoq and neuroscience growth. This shows the core business is performing well, supporting the stock's long-term value.

  This is the main new positive event this period, directly driving the stock's fundamental outlook.

• ▼

  Full-year profit guidance lowered Despite the revenue beat, AbbVie cut its full-year adjusted earnings outlook, partly due to a $291M charge for acquired IPR&D and milestone expenses. This disappointed investors and caused shares to fall 4%, as it signals near-term profit pressure.

  This is the key negative event this period, explaining the immediate stock drop and investor concern.

• ▲

  EU approval of RINVOQ for alopecia areata AbbVie won European approval for RINVOQ in severe alopecia areata, expanding its immunology franchise. This adds a new revenue stream and reinforces RINVOQ's growth potential, which is positive for the stock.

  This is a new regulatory win that expands the market for a key drug, supporting future sales.

• ▼

  Epcoritamab trial setback The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint in the U.S., a setback for AbbVie's oncology pipeline. This could delay or reduce the drug's potential, weighing on sentiment.

  This is a new negative pipeline event that affects future growth prospects.

Based on 8 stories →

• ▲

  EU approval of TEPKINLY for follicular lymphoma The European Commission approved AbbVie's TEPKINLY combination for relapsed follicular lymphoma, a chemotherapy-free option that cut progression risk by 79%. This expands AbbVie's oncology portfolio and adds a new revenue stream, supporting long-term growth.

  New approval directly boosts AbbVie's oncology franchise and future sales.

• ▲

  EU approval of Boey for frown lines Allergan Aesthetics, part of AbbVie, won EU approval for Boey, a fast-acting botulinum toxin for frown lines. This strengthens AbbVie's aesthetics business and offers a new treatment option, potentially driving revenue growth.

  New product approval expands AbbVie's aesthetics portfolio and revenue potential.

• ▲

  Voluntary drug-pricing deals with Trump administration AbbVie agreed to voluntary most-favored-nation pricing with the Trump administration. While this may lower prices for some drugs, AbbVie's newer immunology drugs Skyrizi and Rinvoq are expected to offset Humira's decline, and the deal reduces regulatory uncertainty.

  New pricing agreement affects AbbVie's revenue but is manageable given strong new drugs.

• ▼

  Epcoritamab trial misses overall survival endpoint Genmab and AbbVie confirmed that the Phase 3 EPCORE DLBCL-1 trial did not meet its primary overall survival endpoint in the U.S. This setback could delay or reduce the drug's potential in this indication, weighing on sentiment.

  New negative trial result directly impacts AbbVie's oncology pipeline and investor confidence.

Based on 8 stories →

• ▲

  Apogee acquisition and expanded drug labels drive record high AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, adding a promising immunology drug. It also won approvals to expand Skyrizi and Rinvoq to new patient groups. These moves strengthen future growth and pushed the stock to a 52-week high, adding $43 billion in market value in a week.

  This is the main reason the stock hit a new high and reflects the biggest new development this period.

• ▼

  US Congress opens bipartisan probe into AbbVie's China clinical trials A House committee is investigating AbbVie's clinical trials in China, including sites linked to the Chinese military and in Xinjiang. While no illegal conduct is alleged, the probe could lead to tighter oversight, higher compliance costs, and restrictions on trial locations, potentially delaying drug pipelines and hurting the stock.

  This is a new risk that could negatively affect the stock and was not in earlier reports.

• ▼

  Growth of key drugs Skyrizi and Rinvoq shows signs of slowing Skyrizi's growth decelerated to 29.2% from 31.9%, and Rinvoq's growth slowed to 20.2% from 28.6%. These drugs are critical to AbbVie's post-Humira strategy, and any sustained slowdown could pressure the stock's valuation, which already prices in high growth.

  This is a new concern about the company's growth engine that could weigh on the stock.

• ▲

  Positive late-stage trial results and new drug approvals bolster pipeline AbbVie reported positive Phase 3 data for venetoclax in leukemia and epcoritamab in lymphoma, and won approvals for MAVIRET in hepatitis C, SKYRIZI in pediatric psoriasis, and a new neurotoxin Boey. These advances strengthen the company's oncology and aesthetics portfolios, supporting long-term revenue growth.

  These are new clinical and regulatory wins that reinforce AbbVie's pipeline and future sales potential.

Based on 23 stories →

• ▲

  Apogee acquisition adds promising immunology drug AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining zumilokibart, a potential rival to Dupixent for eczema and asthma. The deal strengthens AbbVie's immunology franchise and pipeline, which investors view as a positive for long-term growth.

  This is the main new event driving ABBV's stock and future prospects.

• ▲

  Deal funded without debt, preserving financial flexibility AbbVie will pay for Apogee entirely from operating cash flow, avoiding new debt. This keeps its balance sheet strong and reduces financial risk, which supports the stock price.

  Shows the acquisition is financially manageable and not a strain.

• ◆

  Near-term earnings dilution, but long-term growth The deal won't add to adjusted earnings per share until 2032, so it may slightly weigh on near-term profits. However, it positions AbbVie for future growth in immunology, balancing the short-term cost with long-term benefit.

  Highlights the trade-off investors are weighing.

• ▲

  Analysts see reasonable premium and strategic fit Citi and other analysts said the 49% premium is not excessive given Apogee's strong data and scarce immunology assets. The deal also fits with AbbVie's existing commercial infrastructure, supporting a positive view.

  Analyst validation reinforces the market's positive reaction.

Based on 6 stories →

• ▲

  Sanofi deal expands pipeline with $1B upfront Regeneron and Sanofi agreed to jointly develop four long-acting immunology therapies, led by REGN20423, in a deal worth up to $8 billion including $1 billion upfront. This brings cash and pipeline growth, supporting future revenue and the stock.

  This is a major new partnership that directly boosts Regeneron's pipeline and cash, a key positive driver.

• ▼

  Securities class action lawsuits weigh on sentiment Multiple law firms filed class actions alleging Regeneron made false statements about its Fianlimab-Libtayo trial, causing investor losses. The legal uncertainty and potential reputational damage pressure the stock, though the company denies wrongdoing.

  These lawsuits are a new negative overhang that could affect investor confidence and lead to financial penalties.

• ▼

  Mixed melanoma trial results lead to pullback Regeneron's melanoma drug trial produced mixed results, causing shares to give back some gains. This setback raises doubts about the drug's potential and adds to pipeline uncertainty, weighing on the stock.

  This is a new clinical setback that directly impacts Regeneron's oncology pipeline and investor expectations.

• ▲

  Buybacks and dividend support shareholder value Regeneron confirmed its quarterly dividend, updated on share repurchases, and reported Q2 results. With the stock trading below fair value estimates, these capital returns and pipeline progress support the shares.

  This shows management's commitment to returning cash and the stock's valuation appeal, a positive for investors.

Based on 10 stories →

• ▲

  Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

  This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

• ▲

  Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

  A positive clinical readout in a major new market area is a key driver of future growth expectations.

• ▼

  Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

  Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

• ▲

  Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

  It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

Based on 7 stories →

• ▲

  Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

  This is the period's biggest positive fundamental driver of REGN's value.

• ▲

  Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

  It is a concrete capital event that improves future profitability.

• ▲

  FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

  A new FDA approval is a fresh product and pipeline milestone for REGN.

• ▼

  Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

  This is the main negative overhang on REGN this period.

Based on 7 stories →

• ▲

  Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

  This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

• ▼

  Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

  This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

• ▼

  Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

  This new analyst commentary underscores pipeline challenges that could pressure the stock.

Based on 7 stories →

• ▲

  CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

  This is a new deal that adds to Regeneron's pipeline and potential future earnings.

• ▲

  Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

  Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

• ▲

  FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

  This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

• ▼

  AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

  This is a new competitive threat that could impact Regeneron's key product, Dupixent.

Based on 7 stories →